Quick Facts

• Therapeutic Domain: Addresses iron deficiency and associated iron deficiency anemia.
• Targeted Conditions: Used for latent or overt iron deficiency anemia in adults and children.
• Specific Contexts: Used to manage iron deficiency during pregnancy, breastfeeding, and following chronic blood loss.

---

Ferplex, containing the agent Ferric Proteinsuccinylate, is a therapeutic agent used for the management of iron deficiency and the related condition, iron deficiency anemia.

The medication is indicated to help address situations where the body’s iron stores are insufficient, leading to a diminished level of red blood cells. Its therapeutic utility extends to various patient populations, including use for both children and adult patients who exhibit latent or overt iron deficiency anemia.

Physicians may utilize this agent to help manage iron deficiency when it is secondary to specific physiological states. These states include periods of pregnancy, the phase of breastfeeding, and conditions involving chronic blood loss where iron depletion is a concern. The treatment aims to support the body’s iron requirements as part of an overall therapeutic strategy.

Regulatory References

1. NIH MedlinePlus guidance

Ferplex (Ferric Proteinsuccinylate) is approved for use in patient populations with confirmed iron deficiency or associated anemia.

Approved Populations

The medicine is officially documented as allowed for Adults and Children for the treatment of latent or overt iron deficiency anemia. Specific allowance is granted for use during physiological states where iron requirements are high, including Pregnancy and Breastfeeding.

Official Contraindications

Ferplex must not be used in patients with specific pre-existing conditions as defined by regulatory labeling:

• Iron Overload: Patients with haemochromatosis, haemosiderosis, or other recognized iron storage disorders.
• Anemias Not Due to Iron Deficiency: Patients with anemias such as aplastic, hemolytic, or sideroblastic anemia.
• Hypersensitivity: Individuals with known allergy or hypersensitivity to the active substance, Ferric Proteinsuccinylate, or to any of the product's excipients.

Eligibility Restrictions and Caution

• Hereditary Disorders: Patients with rare hereditary fructose intolerance must not take this medicine (due to the presence of sorbitol in the formulation).
• Intolerance: Caution is advised for patients with milk protein intolerance, as the active ingredient is bound to a modified milk protein complex.
• Underlying Disease: Caution is necessary in patients with existing peptic ulcers or inflammatory bowel disease.

Interactions with other medicines and products

Documented Interaction Patterns

The interaction profile of Ferric Proteinsuccinylate (an oral iron product) is characterized by a high risk of reduced absorption of both the iron and co-administered medicines, typically due to physicochemical binding (chelation) in the gastrointestinal tract. Regulatory sources identify several substance categories and specific medicines that are subject to these interactions.

---

Interaction-Related Restrictions and Requirements

Reduced Exposure of Co-administered Drugs: Oral iron significantly decreases the absorption of medicines such as Tetracycline and Quinolone antibiotics, Levothyroxine, Bisphosphonates, Penicillamine, and Parkinson's medications like Levodopa. This reciprocal reduction in bioavailability necessitates strict separation of administration timing.

Mandatory Timing Separation: To maintain the necessary exposure, it is often required to take the iron product at least two hours before or two hours after Antacids, and at least two hours before or four hours after Tetracycline antibiotics.

Specific Combinations and Effects: The combination of oral iron with Dimercaprol is specified in regulatory documents as a combination to be avoided. A pharmacodynamic interaction with Chloramphenicol is noted, as it interferes with the incorporation of iron into red blood cells. Additionally, consuming foods like tea, milk, or eggs is documented to impair iron absorption.

Ferplex (Ferric Proteinsuccinylate) works by a dual-action mechanism focusing on pH-dependent delivery and direct engagement of the body's natural iron absorption and utilization machinery.

️ pH-Targeted Delivery and Gastric Protection

This initial mechanistic domain describes how the drug's unique protein carrier complex dictates the site of iron release, ensuring the trivalent iron ( Fe^3+) component remains stable and bound throughout the acidic stomach environment. This controlled delivery minimizes the concentration of reactive, free iron ions at the gastric mucosa, a key step in minimizing the contact between free iron and the sensitive gastric lining. The active ingredient is released only in the neutral-to-alkaline conditions of the duodenum via hydrolysis by pancreatic proteases, thereby preparing the iron for absorption.

---

️ Enterocyte Transporters and Iron Absorption Cascade

Once released in the duodenum, the Fe^3+ engages the Duodenal cytochrome b (DCYTB) enzyme for reduction to the absorbable Fe^2+ state, which is then transported into the enterocyte via Divalent metal transporter 1 (DMT1). Iron is subsequently exported into the circulation through Ferroportin, increasing the iron supply. This cascade directly modulates the Iron Metabolism Pathway, resulting in higher saturation of the systemic carrier Transferrin and replenishment of the storage protein Ferritin.

---

Systemic Utilization and Erythropoiesis Support

The absorbed iron is transported to the bone marrow, where it acts as the essential mineral substrate for Heme Synthesis within developing red blood cells. By providing this component, the mechanism drives the subsequent production of Hemoglobin. The iron supports the Erythropoiesis Pathway, contributing to the production of Hemoglobin-rich cells.

Ferric Proteinsuccinylate is strictly administered via the oral route, typically available as a solution or a capsule. The official administration guidelines focus on optimizing iron absorption and ensuring a sufficient course of therapy.

---

Dosing and Frequency Schedule

Official therapeutic regimens for adults commonly prescribe a daily intake of elemental iron ranging from 40 mg to 80 mg for active treatment. During the treatment phase, the total daily dose is generally instructed to be divided into two separate doses to optimize absorption and tolerability. For maintenance or prophylactic use, a single daily dose of 40 mg of elemental iron is often specified.

---

Preparation and Timing Constraints

The dose should preferably be taken before meals. If using the oral solution, the vial must be shaken, and the dose can be consumed directly or diluted with water or fruit juice. To ensure the full amount of iron is absorbed, the medicine's intake must be separated by at least two hours from known absorption inhibitors, which include dairy products (milk), coffee, and tea, as well as certain oral medications.

---

Duration and Age-Specific Use

The length of the treatment course is determined by the need to fully replenish the body's iron stores, a process that commonly requires a duration of three to six months. For children, a weight-based regimen, such as 4 mg/kg of elemental iron daily, is typically administered and requires specific medical guidance. If a dose is missed, the regular dosing schedule should be resumed with the next scheduled intake, and a double dose must not be taken to compensate.

Research evidence / Overview of studies for Ferplex (Ferric Proteinsuccinylate)

The research for Ferric Proteinsuccinylate has primarily explored its role in the context of Iron Deficiency Anemia (IDA) in the general adult population. The evidence includes numerous Randomized Controlled Trials (RCTs) and is summarized by Systematic Reviews and Meta-Analyses. Researchers examined the agent in trials against other oral iron forms and placebo.

These studies generally examined how hematological biomarkers, such as Hemoglobin (Hb) levels and Serum Ferritin (iron storage), changed during observation periods, typically ranging from 30 to 60 days. Findings describe patterns in the key iron biomarkers measured during the study period. Comparative trials examined the changes in these markers against some conventional oral iron salts, and research provides insight into observed changes in individuals with certain comorbidities.

Evidence in Special Populations

Specific clinical research was studied for addressing iron deficiency in special populations, including pregnant women and pediatric patients (children). These trials were evaluated in cohorts throughout various trimesters and age groups, with follow-up periods extending up to four months. The evidence helps contextualize how patients reported their experience regarding compliance and continuation of the treatment, particularly in these sensitive groups.

Research Gaps and Areas of Uncertainty

The majority of RCTs studied initial changes in iron status, but had follow-up durations that were limited, typically lasting only 30 to 60 days. This means long-term effects are not fully established beyond the short-term change in biomarkers. The overall quality of evidence varies across studies, and scientific reviews highlight several areas where data are still emerging or where certainty remains low. The evidence highlights what is known — and what is still uncertain. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Iron Supplements: MedlinePlus Drug Information

Common questions about Ferplex (Ferric Proteinsuccinylate) (FAQ)

Q: Does this medicine make you sleepy?

Official product information, including the FDA label and European SmPC, reports dizziness and somnolence (sleepiness) as very common side effects. Awareness of these effects is important, as they may impact the ability to perform tasks requiring complete mental alertness.

Q: Can I drink alcohol while taking this medication?

Official product information cautions against the concurrent use of alcoholic drinks with this medication. This is because alcohol may increase central nervous system side effects already associated with this medicine, such as drowsiness and dizziness.

Q: Is it safe long-term?

This medication has been studied in long-term clinical trials. However, regulatory documents highlight the potential for drug dependence and the risk of abuse with continued use. The labeling indicates that awareness of the potential for drug dependence and abuse is recommended for patients on prolonged therapy.

Q: Can children 2 years old use it?

In some regions, official labeling approves this medication for use in treating partial-onset seizures in pediatric patients as young as 1 month of age. However, for most other approved conditions, regulatory information states it is not recommended for patients under 18 years of age.

Q: What should I do if I miss a dose?

Official dosing instructions generally advise that if a dose is missed, it should be taken as soon as it's remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to resume the regular schedule. Taking two doses at once to compensate for a missed dose is generally not advised by product labeling.

Q: Can I use it if I am pregnant or breastfeeding?

Official regulatory documents indicate that the use of this medication during pregnancy is generally not advised due to the potential for fetal harm observed in animal studies. It is also not recommended while breastfeeding because the active ingredient is known to pass into breast milk.

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing Ferplex (Ferric Proteinsuccinylate) oral solution to maintain its stability and safety.

Storage Conditions

The medicine must be stored at a temperature not exceeding 30°C. It must not be refrigerated or frozen, and the container should be protected from heat and light. To ensure safety, Ferplex must be kept out of the sight and reach of children due to the risk of accidental iron overdose.

Disposal

Disposal of any unused or expired product must be carried out in accordance with local requirements. Pharmaceuticals should not be disposed of via wastewater or household trash unless specifically authorized by local waste disposal authorities.